[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Lin TI, Lin JC, Ho ES, Chou MM: Nasopharyngeal carcinoma during pregnancy. Taiwan J Obstet Gynecol; 2007 Dec;46(4):423-6
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasopharyngeal carcinoma during pregnancy.
  • OBJECTIVE: Nasopharyngeal carcinoma, particularly during pregnancy, rarely comes to medical attention before it spreads to the regional lymph nodes.
  • Magnetic resonance imaging examination showed a large soft tissue mass measuring 3 x 2 x 2 cm in the left nasopharynx at 31 weeks of gestation.
  • Punch biopsy of the tumor was done, and the histopathologic report revealed poorly differentiated, non-keratinizing type of squamous cell carcinoma (T4N2M0).
  • The patient received chemotherapy and radiation therapy after delivery.
  • CONCLUSION: The possibility of rare nasopharyngeal carcinoma should be considered in any pregnant woman with presenting symptoms of persistent headache and abnormal nasal discharge, and a detailed thorough investigation is indicated.
  • Successful pregnancy outcome can be achieved after tailored use of a combination of chemotherapy and radiotherapy.
  • [MeSH-major] Carcinoma, Squamous Cell / complications. Nasopharyngeal Neoplasms / complications. Pregnancy Complications, Neoplastic / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Infant, Newborn. Pregnancy. Radiotherapy, Adjuvant. Withholding Treatment

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18182351.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


2. Kong L, Zhang YW, Hu CS, Guo Y: Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma. Chin J Cancer; 2010 May;29(5):551-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
  • BACKGROUND AND OBJECTIVE: Concurrent chemoradiation therapy (CCRT) is the standard treatment for patients with locally advanced nasopharyngeal carcinoma (NPC).
  • The effect of neoadjuvant chemotherapy followed by CCRT has not been determined.
  • Therefore, we conducted 2 phase II studies to evaluate the efficacy and safety of neoadjuvant chemotherapy with a regimen of docetaxel, cisplatin, and 5 fluorouracil (5-Fu) (TPF) followed by radiotherapy and concurrent cisplatin in patients with stage III and IV(A - B) NPC.
  • This article is the preliminary report on treatment related toxicities and response.
  • METHODS: Graded according to the 2002 American Joint Committee on Cancer (AJCC) staging criteria, only patients with stage III or IV(A-B) poorly differentiated or undifferentiated NPC (World Health Organization type II/III) were included.
  • All patients received neoadjuvant chemotherapy with TPF (docetaxel 75 mg/m(2), day 1; cisplatin 75 mg/m(2), day 1; 5 Fu 500 mg/(m2 x day), continuous intravenous infusion for 120 h), every 3 weeks for 3 cycles, followed by weekly cisplatin (40 mg/m(2)) concurrent with radiotherapy.
  • Gross disease planning target volume (PTV), high risk and low risk subclinical PTV doses were prescribed at 70-76 Gy, 66-70 Gy, and 60-61.25 Gy at 1.75-2.0 Gy per fraction.
  • The lower neck or supraclavicular fields may be treated with conventional AP/PA fields for a total of 54 Gy at 1.8 Gy per fraction.
  • Patients were evaluated for tumor response after the completion of neoadjuvant chemotherapy, and at 3 months after radiation according to the Response Evaluation Criteria In Solid Tumors (RECIST).
  • RESULTS: Fifty nine patients were evaluable for treatment response.
  • All patients completed RT to the prescribed dose and 2 cycles of neoadjuvant chemotherapy, with 51 patients (86.4%) completing 3 cycles.
  • The overall response rate in the primary site and the neck region were 94.9% [complete response (CR) in 25.4%] and 100% (CR in 19.6%) after completing neoadjuvant chemotherapy.
  • After a median follow up of 14.3 months, we observed 5 treatment failures and 2 deaths.
  • The rates of grade 3/4 myelosuppression and anorexia/nausea/vomiting during neoadjuvant chemotherapy were 55.9% and 16.9%, respectively.
  • There were no treatment related deaths.
  • CONCLUSIONS: Neoadjuvant chemotherapy with TPF followed by CCRT was well tolerated with a manageable toxicity profile.
  • [MeSH-major] Chemoradiotherapy. Chemotherapy, Adjuvant. Nasopharyngeal Neoplasms / therapy. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Anemia / chemically induced. Anemia / etiology. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / adverse effects. Cisplatin / therapeutic use. Female. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Leukopenia / chemically induced. Leukopenia / etiology. Male. Middle Aged. Nausea / chemically induced. Nausea / etiology. Neoplasm Staging. Neutropenia / chemically induced. Neutropenia / etiology. Radiotherapy, Conformal. Radiotherapy, Intensity-Modulated. Remission Induction. Survival Rate. Taxoids / adverse effects. Taxoids / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20426907.001).
  • [ISSN] 1000-467X
  • [Journal-full-title] Chinese journal of cancer
  • [ISO-abbreviation] Chin J Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Taxoids; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; TPF protocol
  •  go-up   go-down


3. Wang X, Guo Y, Yang S, Wang C, Fu X, Wang J, Mao Y, Zhang J, Li Y: Cellular and molecular mechanisms of photodynamic hypericin therapy for nasopharyngeal carcinoma cells. J Pharmacol Exp Ther; 2010 Sep 1;334(3):847-53
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cellular and molecular mechanisms of photodynamic hypericin therapy for nasopharyngeal carcinoma cells.
  • Hypericin-mediated photodynamic therapy (HY-PDT) has become a potential treatment for tumors and nonmalignant disorders.
  • Some studies reported that HY-PDT could lead to apoptosis in some carcinoma cells.
  • In this study, we evaluated the molecular mechanisms of hypericin associated with light-emitting diode irradiation on the poorly differentiated human nasopharyngeal carcinoma cell line CNE-2 in vitro.
  • Furthermore, we performed genome-wide expression analysis via microarrays at different time points in response to HY-PDT, and we found that differentially expressed genes were highly enriched in the pathways related to reactive oxygen species generation, mitochondrial activity, DNA replication and repair, cell cycle/proliferation, and apoptosis.
  • [MeSH-major] Nasopharyngeal Neoplasms / drug therapy. Perylene / analogs & derivatives. Photochemotherapy / methods. Radiation-Sensitizing Agents / therapeutic use
  • [MeSH-minor] Apoptosis / drug effects. Apoptosis / radiation effects. Caspases / metabolism. Cell Cycle / drug effects. Cell Cycle / radiation effects. Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / radiation effects. DNA Repair. DNA Replication / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Genome-Wide Association Study. Glutathione / metabolism. Humans. Light. Mitochondria / drug effects. Mitochondria / metabolism. Oligonucleotide Array Sequence Analysis. Reactive Oxygen Species / metabolism

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • Hazardous Substances Data Bank. PERYLENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551295.001).
  • [ISSN] 1521-0103
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiation-Sensitizing Agents; 0 / Reactive Oxygen Species; 5QD5427UN7 / Perylene; 7V2F1075HD / hypericin; EC 3.4.22.- / Caspases; GAN16C9B8O / Glutathione
  •  go-up   go-down


Advertisement
4. Guo S, Huang F, Guo P: Construction of folate-conjugated pRNA of bacteriophage phi29 DNA packaging motor for delivery of chimeric siRNA to nasopharyngeal carcinoma cells. Gene Ther; 2006 May;13(10):814-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Construction of folate-conjugated pRNA of bacteriophage phi29 DNA packaging motor for delivery of chimeric siRNA to nasopharyngeal carcinoma cells.
  • Nasopharyngeal carcinoma is a poorly differentiated upper respiratory tract cancer that highly expresses human folate receptors (hFR).
  • Utilizing the engineered left/right interlocking loops, polyvalent dimeric pRNA nanoparticles were constructed using RNA nanotechnology to carry folate, a detection marker, and siRNA targeting at an antiapoptosis factor.
  • Incubation of nasopharyngeal epidermal carcinoma (KB) cells with the dimer resulted in its entry into cancer cells, and the subsequent silencing of the target gene.
  • Such a protein-free RNA nanoparticle with undetectable antigenicity has a potential for repeated long-term administration for nasopharyngeal carcinoma as the effectiveness and specificity were confirmed by ex vivo delivery in the animal trial.

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. ADENOSINE 5'-PHOSPHATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nucleic Acids Res. 2003 Feb 1;31(3):e8 [12560511.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2002;72:415-72 [12206459.001]
  • [Cites] Nature. 2002 Jul 25;418(6896):379-80 [12140542.001]
  • [Cites] J Biol Chem. 2002 Jun 7;277(23):20794-803 [11886855.001]
  • [Cites] Science. 2002 May 17;296(5571):1319-21 [12016316.001]
  • [Cites] J Drug Target. 2001 Apr;9(2):123-39 [11697107.001]
  • [Cites] Science. 2002 Apr 19;296(5567):550-3 [11910072.001]
  • [Cites] Nat Biotechnol. 2005 Aug;23(8):1002-7 [16041363.001]
  • [Cites] Gene Ther. 2005 Jan;12(1):5-11 [15496962.001]
  • [Cites] RNA. 1997 Sep;3(9):1068-79 [9292504.001]
  • [Cites] Mol Cell. 1998 Jul;2(1):149-55 [9702202.001]
  • [Cites] Bioconjug Chem. 1999 May-Jun;10(3):371-8 [10346866.001]
  • [Cites] RNA. 1999 Jun;5(6):805-18 [10376879.001]
  • [Cites] Gene Ther. 2003 Aug;10(15):1258-67 [12858191.001]
  • [Cites] J Nanosci Nanotechnol. 2003 Aug;3(4):295-302 [14598442.001]
  • [Cites] RNA. 2003 Dec;9(12):1562-70 [14624011.001]
  • [Cites] Nat Struct Mol Biol. 2004 Mar;11(3):214-8 [14983173.001]
  • [Cites] Expert Opin Biol Ther. 2004 Mar;4(3):319-27 [15006726.001]
  • [Cites] Science. 1987 May 8;236(4802):690-4 [3107124.001]
  • [Cites] Science. 1991 Nov 29;254(5036):1361-4 [1720569.001]
  • [Cites] J Biol Chem. 1994 Feb 4;269(5):3198-204 [8106354.001]
  • [Cites] Virology. 1994 May 15;201(1):77-85 [8178491.001]
  • [Cites] RNA. 1995 Dec;1(10):1041-50 [8595559.001]
  • [Cites] J Nucl Med. 1996 Jun;37(6):1003-8 [8683292.001]
  • [Cites] Nature. 2001 May 24;411(6836):494-8 [11373684.001]
  • [Cites] Biochemistry. 2000 Dec 19;39(50):15548-55 [11112541.001]
  • [Cites] Adv Drug Deliv Rev. 2000 Oct 31;44(1):71-8 [11035199.001]
  • [Cites] J Biol Chem. 2000 Jun 9;275(23):17510-6 [10748150.001]
  • [Cites] Nature. 2004 Nov 11;432(7014):173-8 [15538359.001]
  • [Cites] Nano Lett. 2005 Sep;5(9):1797-808 [16159227.001]
  • [Cites] Hum Gene Ther. 2005 Sep;16(9):1097-109 [16149908.001]
  • [ErratumIn] Gene Ther. 2006 Nov;13(21):1553
  • (PMID = 16482206.001).
  • [ISSN] 0969-7128
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R01 EB003730; United States / NIBIB NIH HHS / EB / EB003730-03; United States / NIGMS NIH HHS / GM / R01 GM059944-06; United States / NIGMS NIH HHS / GM / R01 GM059944; United States / NIBIB NIH HHS / EB / R01-EB03730; United States / NIGMS NIH HHS / GM / GM059944-06; United States / NIBIB NIH HHS / EB / R01 EB003730-03; United States / NIGMS NIH HHS / GM / R01-GM59944
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Folate Receptors, GPI-Anchored; 0 / RNA, Small Interfering; 0 / Receptors, Cell Surface; 415SHH325A / Adenosine Monophosphate; 935E97BOY8 / Folic Acid
  • [Other-IDs] NLM/ NIHMS183024; NLM/ PMC2840388
  •  go-up   go-down


5. Plaza G, Fogué L, Martínez San Millán J, Martínez Vidal A, Bellas C: [Diagnostic evaluation of nasopharyngeal carcinoma: role of Epstein-Barr virus]. An Otorrinolaringol Ibero Am; 2002;29(1):71-91
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic evaluation of nasopharyngeal carcinoma: role of Epstein-Barr virus].
  • [Transliterated title] Evaluación diagnóstica del carcinoma nasofaríngeo: papel del virus de Epstein-Barr.
  • We present a retrospective series of 27 nasopharyngeal carcinomas, selected from those attended at Ramón y Cajal Hospital between 1977 and 1996, with the aim of review the role of the study of Epstein-Barr virus in the diagnostic process of nasopharyngeal carcinoma.
  • Radiotherapy was employed in all cases, helped by chemotherapy in 20% of them.
  • Of 27 cases of nasopharyngeal carcinoma 4 were differentiated (type I), 2 moderately differentiated (type II) and 22 undifferentiated (type III).
  • Thus, all nasopharyngeal carcinomas were related to Epstein-Barr virus.
  • Expression of LMP-1 seemed to worse the prognosis of nasopharyngeal carcinoma.
  • [MeSH-major] Carcinoma. Nasopharyngeal Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11962004.001).
  • [ISSN] 0303-8874
  • [Journal-full-title] Anales otorrinolaringológicos ibero-americanos
  • [ISO-abbreviation] An Otorrinolaringol Ibero Am
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 60
  •  go-up   go-down


6. Griffin BE: [Nasopharyngeal carcinoma in sub-Saharan Africa: a tribute to Mr. Peter Clifford]. Ai Zheng; 2009 Aug;28(8):785-90
Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nasopharyngeal carcinoma in sub-Saharan Africa: a tribute to Mr. Peter Clifford].
  • Poorly differentiated nasopharyngeal carcinoma (NPC) is a major malignancy in certain areas of Asia.
  • [MeSH-major] Epstein-Barr Virus Infections. Nasopharyngeal Neoplasms
  • [MeSH-minor] Africa South of the Sahara. Antineoplastic Agents, Alkylating / therapeutic use. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / genetics. Burkitt Lymphoma / history. Burkitt Lymphoma / virology. Herpesvirus 4, Human / isolation & purification. History, 20th Century. Humans. Kenya. Mechlorethamine / therapeutic use

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19664323.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Biography; English Abstract; Historical Article; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 50D9XSG0VR / Mechlorethamine
  • [Personal-name-as-subject] Clifford P
  •  go-up   go-down


7. Zhou Q, Olivo M, Lye KY, Moore S, Sharma A, Chowbay B: Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models. Cancer Chemother Pharmacol; 2005 Dec;56(6):569-77
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models.
  • BACKGROUND: Photodynamic therapy (PDT) is a promising therapeutic modality using a tumor localizing photosensitizer and light to destroy tumor cells.
  • PURPOSE: The objective of the present study was to determine whether combination therapy with PDT and antiangiogenic agents (i.e.
  • SU5416 and SU6668) would be more effective in controlling tumor recurrence in a mouse model of human CNE2 poorly differentiated nasopharyngeal carcinoma compared with PDT or antiangiogenic agents administered alone.
  • METHODS: Athymic mice bearing CNE2 tumor xenografts received daily i.p. injections of 20 mg/kg SU5416 or 100 mg/kg SU6668 for 28 consecutive days either alone or following a single hypericin-PDT treatment.
  • RESULTS: Significant inhibition of CNE2 tumor growth was observed in all treatment groups.
  • Differences in 4x tumor growth time, the number of mice with 4x tumor growth, tumor growth inhibition as well as the percent of mice surviving were not statistically significant among individual treatment groups.
  • However, the number of mice with 4x tumor growth observed in SU6668 monotherapy and combined PDT and SU6668 treatment groups was significantly less than that in the control group (P<0.05 and 0.01, respectively).
  • Moreover, compared with the control group, only the combined PDT and SU6668 treatment significantly extended survival of tumor-bearing host mice (P<0.05).
  • CONCLUSIONS: The effectiveness of PDT can be enhanced by antiangiogenic treatment with the synthetic RTK inhibitors.
  • [MeSH-major] Adenocarcinoma / drug therapy. Angiogenesis Inhibitors / therapeutic use. Indoles / therapeutic use. Nasopharyngeal Neoplasms / drug therapy. Photochemotherapy. Protein-Tyrosine Kinases / antagonists & inhibitors. Pyrroles / therapeutic use
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Drug Screening Assays, Antitumor. Gene Expression / drug effects. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Transplantation. Neoplasms, Experimental / drug therapy. Neoplasms, Experimental / metabolism. Neoplasms, Experimental / pathology. Perylene / analogs & derivatives. Perylene / therapeutic use. Proteins / genetics. Proteins / metabolism. Survival Rate

  • Hazardous Substances Data Bank. PERYLENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001166.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Indoles; 0 / Proteins; 0 / Pyrroles; 5QD5427UN7 / Perylene; 71IA9S35AJ / Semaxinib; 7V2F1075HD / hypericin; 9RL37ZZ665 / orantinib; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


8. Koon HK, Chan PS, Wong RN, Wu ZG, Lung ML, Chang CK, Mak NK: Targeted inhibition of the EGFR pathways enhances Zn-BC-AM PDT-induced apoptosis in well-differentiated nasopharyngeal carcinoma cells. J Cell Biochem; 2009 Dec 15;108(6):1356-63
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted inhibition of the EGFR pathways enhances Zn-BC-AM PDT-induced apoptosis in well-differentiated nasopharyngeal carcinoma cells.
  • Epidermal growth factor receptor (EGFR), a receptor often expressed in nasopharyngeal carcinoma (NPC) cells, is one of the recently identified molecular targets in cancer treatment.
  • In the present study, the effects of combined treatment of Zn-BC-AM PDT with an EGFR inhibitor AG1478 were investigated.
  • Well-differentiated NPC HK-1 cells were subjected to PDT with 1 microM of Zn-BC-AM and were irradiated at a light dose of 1 J/cm(2) in the presence or absence of EGFR inhibitor AG1478.
  • Combination therapy with Zn-BC-AM PDT and EGFR inhibitors may further be developed for the treatment of advanced NPC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Metalloporphyrins / therapeutic use. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / metabolism. Photochemotherapy. Photosensitizing Agents / therapeutic use. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Signal Transduction / drug effects

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19816982.001).
  • [ISSN] 1097-4644
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Metalloporphyrins; 0 / Photosensitizing Agents; 0 / Zn-BC-AM; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


9. Kawecki A, Jagielska B, Jarzabski A, Szutkowski Z, Kiprian D, Rolski W, Pawłowska-Sendułka B: [Concomitant radiochemotherapy followed by adjuvant chemotherapy in patients with poorly differentiated nasopharyngeal cancer; tolerance and early results of treatment]. Otolaryngol Pol; 2005;59(5):671-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Concomitant radiochemotherapy followed by adjuvant chemotherapy in patients with poorly differentiated nasopharyngeal cancer; tolerance and early results of treatment].
  • INTRODUCTION: Recently, concomitant radiochemotherapy became a method of choice in patients with poorly differentiated nasopharyngeal cancer.
  • The aim of this study is to estimate tolerance and early results of the concomitant radiochemotherapy followed by adjuvant chemotherapy (modified US Head and Neck Intergroup protocol).
  • METHODS AND MATERIAL: Analysing protocol consist of conventionally fractionated radiotherapy (TD = 70 Gy) given concomitantly with cisplatin (30 mg/m2 daily during 3 days every 3 weeks).
  • This part of treatment was followed by 3 courses of PF (cisplatin + 5-fluorouracil) chemotherapy.
  • Between August 1998 and September 2003 thirty six patients (27 male and 9 female) were qualified to treatment.
  • Tolerance of the adjuvant chemotherapy was worse.
  • Only 44% patients received all three courses of PF chemotherapy.
  • The reasons of incomplete chemotherapy were neutropenia, infections, prolongated acute reactions or performance status decreasing.
  • CONCLUSIONS: Our results confirm high activity of the concomitant radiochemotherapy followed by chemotherapy in patients with poorly differentiated nasopharyngeal cancer.
  • Those results confirm also high toxicity of this regimen, what suggest very careful patients qualification to treatment.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Male. Middle Aged. Radiotherapy Dosage. Radiotherapy, Adjuvant. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16471182.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


10. Sumitsawan Y, Chaiyasate S, Chitapanarux I, Anansuthiwara M, Roongrotwattanasiri K, Vaseenon V, Tooncam H: Late complications of radiotherapy for nasopharyngeal carcinoma. Auris Nasus Larynx; 2009 Apr;36(2):205-9
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late complications of radiotherapy for nasopharyngeal carcinoma.
  • OBJECTIVE: To evaluate and assemble late complications of radiotherapy in cases of nasopharyngeal cancer.
  • The mean pre- and post-treatment body mass indexes (BMI) were 22.5+/-4 (15-35.6), and 19.8+/-3.2 (12.9-34.5; P<0.05).
  • Most of the patients (92%) had undifferentiated (50.5%) and poorly differentiated (41.5%) squamous cell carcinoma.
  • Chemotherapy was given to 145 patients (72.5%).
  • The mean post-radiation period in the added chemotherapy group was lower than the group treated with radiation alone (2.9+/-2.7 years vs. 5.4+/-4.4 years, P<.05).
  • Added chemotherapy increased the complication severity significantly for the skin (P<0.05).
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Nasopharyngeal Neoplasms / radiotherapy. Radiation Injuries / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Chemotherapy, Adjuvant. Child. Cohort Studies. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prospective Studies. Quality of Life. Radiotherapy Dosage. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18635325.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


11. Ali SM, Olivo M, Yuen GY, Chee SK: Photodynamic-induced apoptosis of human nasopharyngeal carcinoma cells using Hypocrellins. Int J Oncol; 2001 Sep;19(3):633-43
Hazardous Substances Data Bank. PERYLENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic-induced apoptosis of human nasopharyngeal carcinoma cells using Hypocrellins.
  • In this study, we have examined the photodynamic effects of Hypocrellin A and B compounds in poorly differentiated (CNE2) and moderately differentiated (TW0-1) human nasopharyngeal carcinoma (NPC) cells.
  • In conclusion, this study identifies both Hypocrellins (A and B) as potent and promising photosensitizers for the treatment of NPC.
  • [MeSH-major] Apoptosis. Nasopharyngeal Neoplasms / drug therapy. Perylene / therapeutic use. Photochemotherapy. Photosensitizing Agents / therapeutic use. Quinones / therapeutic use. Tumor Cells, Cultured / drug effects
  • [MeSH-minor] Annexin A5 / chemistry. Blotting, Western. Caspase 3. Caspase Inhibitors. Caspases / metabolism. Cell Differentiation / drug effects. DNA, Neoplasm / analysis. Dose-Response Relationship, Drug. Enzyme Inhibitors / pharmacology. Flow Cytometry. Humans. Phosphatidylserines / metabolism. Poly(ADP-ribose) Polymerase Inhibitors. Poly(ADP-ribose) Polymerases / metabolism

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11494047.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Caspase Inhibitors; 0 / DNA, Neoplasm; 0 / Enzyme Inhibitors; 0 / Phosphatidylserines; 0 / Photosensitizing Agents; 0 / Poly(ADP-ribose) Polymerase Inhibitors; 0 / Quinones; 123940-54-5 / hypocrellin B; 5QD5427UN7 / Perylene; 77029-83-5 / hypocrellin A; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


12. Beldjilali Y, Benhadji KA, Boukerche A, Khellafi H, Abdelaoui A, Betkaoui F, Tourabi ZK, Kaïd MY, Djellali L, Yamouni M: First results of induction chemotherapy with cisplatin, docetaxel, and capecitabine for the treatment of nasopharyngeal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):6045

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First results of induction chemotherapy with cisplatin, docetaxel, and capecitabine for the treatment of nasopharyngeal carcinoma.
  • : 6045 Background: The purpose of this phase II study is to assess a new induction chemotherapy regimen combining cisplatin (P), docetaxel (T), and capecitabine (X) in advanced nasopharyngeal carcinoma.
  • METHODS: Previously untreated patients (pts) with histological diagnosed locally advanced nasopharyngeal carcinoma (stages III, IVA, and IVB UICC 2002) received induction chemotherapy associating P 75 mg/m<sup>2</sup>, T 75 mg/m<sup>2</sup>, both on day 1 and X 1,000 mg/m<sup>2</sup>/d days 1-14.
  • Induction chemotherapy was followed by concurrent chemo-radiotherapy: P 75 mg/m<sup>2</sup> days 1, 22, 42 and radiotherapy (65-70 Gy) 4 to 6 weeks after the fourth cycle of induction treatment.
  • 30 pts (75%) had an undifferentiated carcinoma of nasopharyngeal type (UCNT) and 10 pts (25%) a poorly differentiated nasopharyngeal carcinoma.
  • CONCLUSIONS: PTX induction chemotherapy resulted on a high response rate with manageable toxicity.
  • Outcome of patients after chemoradiotherapy is awaited to evaluate the effectiveness of this new treatment modality.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961921.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Sze WM, Lee AW, Tong M, Ng C, Soong I, Chan K, Yeung R, Yau TK: Preliminary experience on treating advanced nasopharyngeal carcinoma (NPC) affecting/abutting neurological structures with induction chemotherapy followed by concurrent chemo-radiation with accelerated fractionation. J Clin Oncol; 2004 Jul 15;22(14_suppl):5525

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary experience on treating advanced nasopharyngeal carcinoma (NPC) affecting/abutting neurological structures with induction chemotherapy followed by concurrent chemo-radiation with accelerated fractionation.
  • : 5525 Background: To study the possibility of improving treatment tolerance and outcome for NPC with extensive infiltration affecting/ abutting neurological structures by induction chemotherapy followed by concurrent chemo-radiation with accelerated fractionation.
  • Ninty-four percent of patients had UICC (5<sup>th</sup> edition) Stage IVA-B and 6% had Stage III disease.
  • Thirty-two patients (97%) had undifferentiated carcinoma and only 1 patient had well differentiated squamous cell carcinoma.
  • The chemotherapy plan included 3 cycles of Cisplatin (80 mg/m<sup>2</sup> ) and Gemcitabine (1250 mg/m<sup>2</sup> D1,8) for induction phase, and 2 cycles of Cisplatin (100 mg/m<sup>2</sup> D1) for the concurrent phase.
  • All patients were irradiated to a total dose of 70 Gy using 3-D conformal techniques and accelerated fractionation at 2 Gy per fraction, 6 daily fractions per week, throughout the whole course.
  • RESULTS: All patients completed the intended radiotherapy dose and the median overall treatment time was 41 days (range: 39-53).
  • The mean weight loss during the whole course of treatment was 11% of the initial body weight.
  • The chemotherapy toxicities and compliance are shown in table 1.
  • CONCLUSIONS: The early treatment results achieved for this very poor prognostic group was very encouraging, but late toxicity has yet to be fully assessed and confirmation of therapeutic gain by prospective randomized trial is warranted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013949.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Li P, Ai P, Chen L, Yang Y, Li Z, Zhang H, Xu Y, Hong Y, Hao D: [Analysis on clinical data of 677 death cases with nasopharyngeal carcinoma]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2002 Jan;16(1):15-6
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis on clinical data of 677 death cases with nasopharyngeal carcinoma].
  • OBJECTIVE: To study the death causes in 677 patients with nasopharyngeal carcinoma (NPC).
  • The pathological type was mostly poorly differentiated squamous cell carcinoma.
  • The patients treated by radiotherapy combined with chemotherapy survived longer than those treated by radiotherapy alone (P < 0.05).
  • The majority of the patients died of distal metastasis (372, 54.9%) and local-regional lymph node uncontrolled (142, 20.9%) after treatment.
  • CONCLUSION: The main death causes of the patients with NPC in our investigation were distal metastasis and local-regional recurrence.
  • The treatment of radiotherapy plus chemotherapy probably increases survival time and reduces the death rate in patients with NPC.
  • [MeSH-major] Carcinoma, Squamous Cell / mortality. Nasopharyngeal Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Cause of Death. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11944472.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


15. Dong XR, Zhang T, Fan L, Zhang S, Wu G: Parotid gland metastasis of nasopharyngeal carcinoma: case report and review of the literature. J Int Med Res; 2009 Nov-Dec;37(6):1994-9
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parotid gland metastasis of nasopharyngeal carcinoma: case report and review of the literature.
  • Parotid metastasis of nasopharyngeal carcinoma (NPC) is extremely rare.
  • Histopathological examination of a partial excision of the mass on the right parotid and the neoplasm in the pharynx nasalis revealed poorly differentiated squamous cell carcinoma.
  • The patient received radiotherapy and concurrent chemotherapy.
  • Grade 2 skin reaction, grade 2 oropharyngeal mucositis and grade 3 xerostomia were detected during treatment.
  • The patient achieved a complete clinical response by 1 month after treatment.
  • [MeSH-major] Nasopharyngeal Neoplasms / pathology. Parotid Neoplasms / secondary
  • [MeSH-minor] Adult. Dose-Response Relationship, Radiation. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20146900.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 20
  •  go-up   go-down


16. Han F, Wang HY, Xia YF, Liu MZ, Zhao C, Lu TX: [Correlation of DNA ploidy in fresh tumor tissues to prognosis of nasopharyngeal carcinoma]. Ai Zheng; 2007 Sep;26(9):1015-9
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation of DNA ploidy in fresh tumor tissues to prognosis of nasopharyngeal carcinoma].
  • BACKGROUND & OBJECTIVE: Because of the heterogeneity of nasopharyngeal carcinoma (NPC), current TNM staging system could not indicate the prognosis of individual patients.
  • 2000, the DNA ploidy in fresh NPC samples from 53 naive NPC patients with poorly differentiated squamous cell carcinoma was analyzed by flow cytometry (FCM).
  • Of the 53 patients, 32 received radiotherapy alone, 21 received 1 course of chemotherapy (cisplatin plus 5-fluorouracil) at the end of the 4th week of radiotherapy.
  • The differences in age, sex, clinical stage, N stage, and chemotherapy were not significant between diploid group and heteroploid group (P>0.05).
  • [MeSH-major] Aneuploidy. Carcinoma, Squamous Cell / genetics. DNA, Neoplasm / genetics. Diploidy. Nasopharyngeal Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy, High-Energy. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17927864.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


17. Xian LJ, Jian S, Cao QY, Ye YL, Liu XH, Li XM, Lévi F: Circadian rhythms of DNA synthesis in nasopharyngeal carcinoma cells. Chronobiol Int; 2002 Jan;19(1):69-76
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circadian rhythms of DNA synthesis in nasopharyngeal carcinoma cells.
  • Nasopharyngeal carcinoma (NPC) occurs frequently in southern China.
  • The circadian rhythm of DNA synthesis of a poorly differentiated NPC human cell line (CNE2) was investigated as an experimental prerequisite for designing chrono-chemotherapy schedules for patients with this disease.
  • The average proportion of tumor cells in G1, S or G2-M phase varied according to circadian time with statistical significance.
  • Inter-individual variability in peak time was large, possibly due to relatively sparse sampling time.
  • Nevertheless, no more than 6% of the time series displayed a maximum at 3 HALO for G1, 21 HALO for S and 15 HALO for G2-M.
  • The mechanisms involved in this rhythm and its relevance to the chrono-chemotherapy of patients deserve further investigation.
  • [MeSH-major] Circadian Rhythm / physiology. DNA, Neoplasm / biosynthesis. Nasopharyngeal Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11962687.001).
  • [ISSN] 0742-0528
  • [Journal-full-title] Chronobiology international
  • [ISO-abbreviation] Chronobiol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


18. Oh JL, Vokes EE, Kies MS, Mittal BB, Witt ME, Weichselbaum RR, Haraf DJ: Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol; 2003 Apr;14(4):564-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer.
  • BACKGROUND: Since 1990, we have treated patients with advanced nasopharyngeal cancer with induction chemotherapy and concomitant chemoradiotherapy.
  • PATIENTS AND METHODS: From 1990 to 1999, 27 patients with locoregionally advanced nasopharyngeal cancer were treated with induction chemotherapy followed by concomitant chemoradiotherapy.
  • By histology, 63% were poorly differentiated carcinoma and 37% squamous cell carcinoma.
  • Three cycles of induction chemotherapy consisting of cisplatin, 5-fluorouracil, leucovorin and interferon-alpha2b were administered, followed by concomitant chemoradiotherapy consisting of seven cycles of 5-fluorouracil, hydroxyurea and once-daily radiotherapy (FHX) on a week-on week-off schedule.
  • The median radiotherapy dose was 70 Gy.
  • RESULTS: Clinical response to induction chemotherapy was 100%, 54.2% complete response (CR) and 45.8% partial response.
  • Clinical and/or pathological (37% of all patients had post-treatment biopsy with or without neck dissection) CR after FHX was 100%.
  • Four patients died of unrelated illnesses and had no evidence of disease with respect to their nasopharyngeal cancer.
  • Thirty-three per cent of patients required a reduction in the chemotherapy dose due to acute toxicity.
  • CONCLUSIONS: Treatment of locoregionally advanced nasopharyngeal cancer with induction chemotherapy followed by concomitant chemoradiotherapy resulted in excellent overall survival with acceptable toxicity.

  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2003 Apr;14(4):508-9 [12649094.001]
  • [CommentIn] Ann Oncol. 2004 Apr;15(4):689; author reply 689-90 [15033682.001]
  • (PMID = 12649102.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon-alpha; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


19. Du HY, Olivo M, Chen YJ, Yip G, Tan PH, Matsumoto K, Tsujimoto M, Bay BH: Expression of Y-Box binding protein-1 following hypericin-mediated photodynamic therapy in well-differentiated nasopharyngeal cancer in vivo. Int J Mol Med; 2005 Nov;16(5):865-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Y-Box binding protein-1 following hypericin-mediated photodynamic therapy in well-differentiated nasopharyngeal cancer in vivo.
  • The purpose of this study was to determine if YB-1 levels are altered in photodynamic therapy (PDT)-treated nasopharyngeal cancer (NPC) cells.
  • In this report, we show for the first time that YB-1 is expressed at both the mRNA and protein levels in well-differentiated NPC in vivo.
  • YB-1 mRNA expression in tumor tissues from a murine well-differentiated HK1/NPC model showed no significant difference in mRNA levels following hypericin-PDT.
  • Localization of the YB-1 protein by immuno-histochemistry revealed the presence of cytoplasmic YB-1 in the more mature and better differentiated cells of the untreated group, as well as cells that survived PDT treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Nasopharyngeal Neoplasms / drug therapy. Perylene / analogs & derivatives. Photochemotherapy. Radiation-Sensitizing Agents / therapeutic use
  • [MeSH-minor] Animals. Carcinoma / drug therapy. Carcinoma / genetics. Carcinoma / pathology. Humans. Male. Mice. Mice, Inbred BALB C. RNA, Messenger / analysis. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PERYLENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16211256.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Messenger; 0 / Radiation-Sensitizing Agents; 5QD5427UN7 / Perylene; 7V2F1075HD / hypericin
  •  go-up   go-down


20. Jiang P, Gan M, Huang H, Shen X, Wang S, Yao K: Proteome analysis of antiproliferative mechanism of 12-O-tetradecanoylphorbol 13-acetate on cultured nasopharyngeal carcinoma CNE2 cells. J Proteome Res; 2005 Mar-Apr;4(2):599-605
Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteome analysis of antiproliferative mechanism of 12-O-tetradecanoylphorbol 13-acetate on cultured nasopharyngeal carcinoma CNE2 cells.
  • 12-O-Tetradecanoyl-phorbol-13-acetate (TPA) is a plant derivative with multiple function as tumor promoter, differentiation revulsant or leukemia therapy drug.
  • Many studies have focused on the mechanism of TPA stimulation in tumor promotion of mouse models or terminal differentiation of leukemia cells, but the effect of TPA on nasopharyngeal carcinoma (NPC) remains unclear, while TPA was considered to be associated with NPC development.
  • In the present study, we employed proteomics techniques to study protein changes of a poorly differentiated squamous carcinoma cell line-CNE2 of human NPCs cells induced by TPA.
  • [MeSH-major] Cell Division / drug effects. Nasopharyngeal Neoplasms / pathology. Proteome. Tetradecanoylphorbol Acetate / pharmacology

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15822940.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Proteome; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


21. Lin ZH, Xia HP, Fu M, Liao WM, Lin T, Chen XG, Wang HX, Yang HL: [Study on effect of sho-saiko-to compound on growth of nasopharyngeal carcinoma cells in CNE-bearing nude mice]. Zhongguo Zhong Yao Za Zhi; 2008 Nov;33(22):2670-4
Genetic Alliance. consumer health - Nasopharyngeal carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on effect of sho-saiko-to compound on growth of nasopharyngeal carcinoma cells in CNE-bearing nude mice].
  • OBJECTIVE: To investigate the role of sho-saiko-to compound (SSTC) on the growth of the well-differentiated squamous cell line 1 of nasopharyngeal carcinoma (CNE-1) and well-differentiated CNE-2 in tumor-bearing nude mouse, and try to supply scientific data for its clinical development.
  • The inhibition rate was increased as the concentration and culture time increasing.
  • It may be a new compound of Chinese medicine for nasopharyngeal carcinoma therapy.
  • [MeSH-major] Carcinoma / drug therapy. Drugs, Chinese Herbal / pharmacology. Nasopharyngeal Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19216169.001).
  • [ISSN] 1001-5302
  • [Journal-full-title] Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica
  • [ISO-abbreviation] Zhongguo Zhong Yao Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal
  •  go-up   go-down


22. Koon HK, Chan PS, Wu ZG, Wong RN, Lung ML, Chang CK, Mak NK: Role of mitogen-activated protein kinase in Zn-BC-AM PDT-induced apoptosis in nasopharyngeal carcinoma cells. Cell Biochem Funct; 2010 Apr;28(3):239-48
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of mitogen-activated protein kinase in Zn-BC-AM PDT-induced apoptosis in nasopharyngeal carcinoma cells.
  • Photodynamic therapy (PDT) with a recently developed photosensitizer Zn-BC-AM was found to effectively induce apoptosis in a well-differentiated nasopharyngeal carcinoma (NPC) HK-1 cell line.
  • A commonly used p38 MAPK/JNK pharmacological inhibitor PD169316 was found to reduce PDT-induced apoptosis of HK-1 cells.
  • Taken together, the results suggest that inhibition of p38beta and ERK may enhance the therapeutic efficacy of Zn-BC-AM PDT on NPC cells.
  • [MeSH-major] Apoptosis / drug effects. JNK Mitogen-Activated Protein Kinases / metabolism. Metalloporphyrins / pharmacology. Nasopharyngeal Neoplasms. Photochemotherapy / methods. Photosensitizing Agents / pharmacology. p38 Mitogen-Activated Protein Kinases / metabolism

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 John Wiley & Sons, Ltd.
  • (PMID = 20373469.001).
  • [ISSN] 1099-0844
  • [Journal-full-title] Cell biochemistry and function
  • [ISO-abbreviation] Cell Biochem. Funct.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; 0 / Metalloporphyrins; 0 / Photosensitizing Agents; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Small Interfering; 0 / Zn-BC-AM; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


23. Radhakrishnan V, Thulkar S, Karunanithi S, Tanveer N, Bakhshi S: Nasopharyngeal carcinoma with splenic and cystic liver metastases in a pediatric patient: 18F-FDG PET-CT findings. Pediatr Radiol; 2010 Dec;40 Suppl 1:S79-82
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasopharyngeal carcinoma with splenic and cystic liver metastases in a pediatric patient: 18F-FDG PET-CT findings.
  • Pediatric nasopharyngeal carcinoma (NPC) is rare and usually poorly differentiated.
  • The liver metastases closely resembled benign cystic liver disease on imaging; however, they showed intense uptake similar to other metastatic sites on positron emission tomography (PET) scan.
  • The boy responded clinically to platinum-based chemotherapy, and all the baseline PET-positive lesions became negative.
  • [MeSH-major] Carcinoma / diagnosis. Carcinoma / secondary. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Nasopharyngeal Neoplasms / diagnosis. Splenic Neoplasms / diagnosis. Splenic Neoplasms / secondary
  • [MeSH-minor] Adolescent. Fluorodeoxyglucose F18. Humans. Lymphatic Metastasis. Male. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2005 Dec;27(12):670-1 [16344674.001]
  • [Cites] Arch Pathol Lab Med. 2000 Apr;124(4):526-30 [10747308.001]
  • [Cites] Onkologie. 2008 Nov;31(11):574-5 [19145087.001]
  • [Cites] Arch Pathol Lab Med. 2007 Jun;131(6):965-9 [17550328.001]
  • [Cites] Br J Radiol. 1998 Nov;71(851):1205-7 [10434918.001]
  • [Cites] World J Gastroenterol. 2008 Jun 21;14(23):3616-20 [18595127.001]
  • [Cites] Lancet Oncol. 2003 Jan;4(1):13-21 [12517535.001]
  • [Cites] Onkologie. 2008 Nov;31(11):635-6 [19145100.001]
  • (PMID = 20922367.001).
  • [ISSN] 1432-1998
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


24. Park KA, Oh SY: Nasopharyngeal carcinoma presenting with rapidly progressive severe binocular optic neuropathy and periocular pain in a young man. J Neuroophthalmol; 2010 Jun;30(2):150-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasopharyngeal carcinoma presenting with rapidly progressive severe binocular optic neuropathy and periocular pain in a young man.
  • Nasopharyngoscopy disclosed a soft tissue lesion filling the apex of the nasopharynx and the posterior portion of the ethmoid sinus with associated sinusitis.
  • Biopsy demonstrated a moderately differentiated squamous cell carcinoma believed to have originated in the nasopharynx.
  • This is the first case of bilateral severe optic neuropathy in nasopharyngeal carcinoma invading the skull base.
  • [MeSH-major] Carcinoma / complications. Carcinoma / pathology. Facial Pain / etiology. Nasopharyngeal Neoplasms / complications. Nasopharyngeal Neoplasms / pathology. Optic Nerve Diseases / etiology
  • [MeSH-minor] Adult. Blindness / etiology. Diagnosis, Differential. Diagnostic Errors / prevention & control. Disease Progression. Drug Therapy. Dura Mater / pathology. Ethmoid Sinus / pathology. Eye / physiopathology. Humans. Magnetic Resonance Imaging. Male. Nasopharynx / pathology. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / physiopathology. Optic Nerve / pathology. Optic Nerve / physiopathology. Sella Turcica / pathology. Skull Base Neoplasms / secondary. Sphenoid Bone / pathology. Time Factors. Vision, Low / etiology

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • MedlinePlus Health Information. consumer health - Optic Nerve Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20414132.001).
  • [ISSN] 1536-5166
  • [Journal-full-title] Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  • [ISO-abbreviation] J Neuroophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Ensley JF, Youssef E, Kim H, Yoo G: Locally advanced nasopharyngeal cancer. Curr Treat Options Oncol; 2001 Feb;2(1):15-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locally advanced nasopharyngeal cancer.
  • The results of this study have defined the new standard of treatment for the group of patients studied.
  • Patients with untreated, locally advanced stages III and IV NPC were randomized to a conventional course of radiation, or to radiation given concurrently with chemotherapy followed by three courses of combination chemotherapy.
  • The considerable improvement in OS versus PFS for the patient group receiving radiation alone is accounted for primarily by re-treatment with concurrent radiation-chemotherapy, combination chemotherapy, and isolated salvage neck dissections.
  • Highly significant differences in local control (41% vs 14%) and distant metastases (35% vs 13%) were demonstrated in favor of the chemoradiation treatment arm.
  • Although many patients had a significant history of tobacco exposure with or without alcohol use or abuse, only 24% had keratinizing or well-differentiated squamous (World Health Organization I) type tumors.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Nasopharyngeal Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Health Behavior. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Survival Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Oncol. 1994 Jun;21(3):382-97 [8209270.001]
  • [Cites] Histopathology. 1998 Aug;33(2):117-22 [9762543.001]
  • [Cites] Oncology (Williston Park). 2000 Aug;14(8):1223-30; discussion 1232-7, 1239-42 [10989829.001]
  • [Cites] Int J Cancer. 1999 Oct 8;83(2):210-4 [10471529.001]
  • [Cites] Cancer. 1983 Aug 15;52(4):602-5 [6683121.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Apr;6(4):401-7 [7390921.001]
  • [Cites] Cancer Res. 1994 Aug 1;54(15):4003-6 [8033130.001]
  • [Cites] Am J Pathol. 1998 Apr;152(4):865-9 [9546345.001]
  • [Cites] Laryngoscope. 2000 Jan;110(1):93-7 [10646722.001]
  • [Cites] Cancer. 1998 Dec 1;83(11):2270-83 [9840526.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):255-61 [10640954.001]
  • [Cites] Head Neck. 1998 Oct;20(7):640-4 [9744466.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):463-9 [8655368.001]
  • [Cites] Int J Cancer. 1995 May 4;61(3):316-20 [7729941.001]
  • [Cites] Am J Pathol. 1995 Jun;146(6):1355-67 [7778675.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1715-22 [10430074.001]
  • [Cites] Histol Histopathol. 1997 Jan;12(1):9-18 [9046038.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4B):2849-54 [9713473.001]
  • [Cites] Cancer Res. 1992 Sep 1;52(17):4787-90 [1511442.001]
  • [Cites] Cancer Res. 1996 Jun 15;56(12):2721-5 [8665502.001]
  • [Cites] Br J Cancer. 2000 Jun;82(12):1946-51 [10864202.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):569-77 [7558945.001]
  • [Cites] Int J Cancer. 1999 Oct 29;83(3):305-8 [10495420.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):597-601 [10524411.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(2):261-70 [1587745.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):901-5 [10571196.001]
  • [Cites] Oral Oncol. 2000 Jan;36(1):8-16 [10889913.001]
  • [Cites] Acta Otorhinolaryngol Belg. 1999;53(3):253-7 [10635404.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Jul;6(7):493-7 [9232335.001]
  • [Cites] Anticancer Res. 1992 Nov-Dec;12(6B):1957-63 [1295443.001]
  • [Cites] Cancer. 1998 Dec 1;83(11):2284-92 [9840527.001]
  • [Cites] Am J Otolaryngol. 1990 Nov-Dec;11(6):393-7 [2281841.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Feb;16(2):301-5 [2921129.001]
  • [Cites] Cancer. 1987 Jan 15;59(2):259-65 [3802013.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2039-43 [7743498.001]
  • [Cites] Oral Oncol. 1998 May;34(3):211-8 [9692056.001]
  • [Cites] Cancer. 1996 Apr 15;77(8):1419-26 [8608524.001]
  • [Cites] Laryngoscope. 1999 May;109(5):810-4 [10334236.001]
  • [Cites] Am J Clin Oncol. 1986 Aug;9(4):281-91 [3751965.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):8-12 [10646842.001]
  • [Cites] Int J Cancer. 2000 Apr 15;86(2):244-50 [10738252.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1985 Oct;11(10):1789-93 [2412999.001]
  • [Cites] J Clin Oncol. 1988 Sep;6(9):1401-10 [3047335.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 May;13(5):679-85 [3570892.001]
  • [Cites] Oncogene. 1993 Mar;8(3):791-5 [8437863.001]
  • [Cites] Otolaryngol Head Neck Surg. 1983 Jun;91(3):255-62 [6308537.001]
  • [Cites] Cancer. 1988 Mar 15;61(6):1117-24 [3342372.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1310-7 [9552031.001]
  • [Cites] Am J Clin Oncol. 1988 Aug;11(4):427-30 [2457306.001]
  • [Cites] Mol Carcinog. 1997 Feb;18(2):78-88 [9049183.001]
  • [Cites] Br J Cancer. 1998;77(3):456-60 [9472643.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1324-30 [10715304.001]
  • [Cites] Cancer. 1990 Oct 15;66(8):1789-95 [2208035.001]
  • [Cites] Int J Cancer. 1998 Oct 5;78(2):153-6 [9754644.001]
  • [Cites] Cancer. 1988 Jun 1;61(11):2338-41 [3365661.001]
  • [Cites] Cancer. 1996 Jun 15;77(12):2423-31 [8640688.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1999 Nov;125(11):1229-34 [10555694.001]
  • [Cites] Acta Otolaryngol. 1994 Jan;114(1):105-9 [8128845.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):261-71 [10030248.001]
  • [Cites] Crit Rev Oncol Hematol. 2000 Apr;34(1):27-53 [10781747.001]
  • [Cites] Cancer Res. 1996 Jul 15;56(14):3225-9 [8764112.001]
  • (PMID = 12057137.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Review
  • [Publication-country] United States
  • [Number-of-references] 64
  •  go-up   go-down


26. Lee YM, Ting CM, Cheng YK, Fan TP, Wong RN, Lung ML, Mak NK: Mechanisms of 2-methoxyestradiol-induced apoptosis and G2/M cell-cycle arrest of nasopharyngeal carcinoma cells. Cancer Lett; 2008 Sep 18;268(2):295-307
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanisms of 2-methoxyestradiol-induced apoptosis and G2/M cell-cycle arrest of nasopharyngeal carcinoma cells.
  • This study aims to examine the anti-tumour activities of 2ME2 on the poorly differentiated HONE-1 NPC cell line.
  • Kinetics studies revealed that 2ME2 induced a time-dependent inhibition of extracellular signal-regulated protein kinase (ERK) and an activation of c-jun N-terminal kinases (JNKs).
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Cell Division / drug effects. Estradiol / analogs & derivatives. G2 Phase / drug effects. Nasopharyngeal Neoplasms / drug therapy
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation / drug effects. Flow Cytometry. Humans. JNK Mitogen-Activated Protein Kinases / metabolism. MAP Kinase Signaling System / drug effects. Oxidative Stress. Superoxide Dismutase / physiology

  • Genetic Alliance. consumer health - Nasopharyngeal carcinoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18492602.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4TI98Z838E / Estradiol; 6I2QW73SR5 / 2-methoxyestradiol; EC 1.15.1.1 / Superoxide Dismutase; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases
  •  go-up   go-down


27. Ali SM, Chee SK, Yuen GY, Olivo M: Photodynamic therapy induced Fas-mediated apoptosis in human carcinoma cells. Int J Mol Med; 2002 Mar;9(3):257-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy induced Fas-mediated apoptosis in human carcinoma cells.
  • Photodynamic therapy (PDT) is a clinical approach that utilizes light-activated drugs for the treatment of a variety of pathologic conditions.
  • Human poorly (CNE2) and moderately differentiated (TW0-1) human nasopharyngeal carcinoma (NPC) cells undergo rapid apoptosis when treated with PDT sensitized with Hypocrellin A (HA) and Hypocrellin B (HB).
  • [MeSH-major] Antigens, CD95 / metabolism. Carcinoma / pathology. Carcinoma / therapy. Nasopharyngeal Neoplasms / pathology. Nasopharyngeal Neoplasms / therapy. Perylene / administration & dosage. Perylene / analogs & derivatives. Photochemotherapy. Photosensitizing Agents / administration & dosage. Quinones / administration & dosage
  • [MeSH-minor] Apoptosis / drug effects. Caspase 3. Caspases / metabolism. Cytochrome c Group / metabolism. Fas Ligand Protein. Humans. Membrane Glycoproteins / metabolism. Membrane Potentials / drug effects. Mitochondria / drug effects. Mitochondria / metabolism. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. PERYLENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11836632.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Cytochrome c Group; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Membrane Glycoproteins; 0 / Photosensitizing Agents; 0 / Quinones; 5QD5427UN7 / Perylene; 77029-83-5 / hypocrellin A; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


28. Ali SM, Olivo M, Yuen GY, Chee SK: Apoptosis induced by photosensitizers (Perylquinone derivatives) in human carcinoma cells: a possible relevance to photodynamic therapy. Asian J Surg; 2002 Jan;25(1):18-26
Hazardous Substances Data Bank. PERYLENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptosis induced by photosensitizers (Perylquinone derivatives) in human carcinoma cells: a possible relevance to photodynamic therapy.
  • In this study, we attempt to elucidate the photodynamic effects of HA and HB compounds in poorly differentiated (CNE2) and moderately differentiated (TW0-1) human nasopharyngeal carcinoma (NPC) cells as well as human mucosal colon (CCL-220.1) and bladder (SD) cells.
  • Using these cell lines we investigated few hall marks of apoptotic commitments in a drug and light dose dependent manner.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17585441.001).
  • [ISSN] 1015-9584
  • [Journal-full-title] Asian journal of surgery
  • [ISO-abbreviation] Asian J Surg
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Quinones; 123940-54-5 / hypocrellin B; 5QD5427UN7 / Perylene; 77029-83-5 / hypocrellin A
  •  go-up   go-down


29. Paulino AF, Singh B, Carew J, Shah JP, Huvos AG: Epstein-Barr virus in squamous carcinoma of the anterior nasal cavity. Ann Diagn Pathol; 2000 Feb;4(1):7-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus in squamous carcinoma of the anterior nasal cavity.
  • Squamous carcinoma is the most common malignancy of the head and neck, but it rarely occurs in the nasal vestibule.
  • Epstein-Barr virus (EBV) has been detected in and is causally linked to various head and neck tumors, particularly nasopharyngeal carcinoma.
  • The possible role of EBV in squamous carcinoma of the anterior nasal cavity, particularly of the nasal vestibule, has not been previously investigated.
  • Histologic sections from 17 patients with nasal vestibular squamous carcinoma were examined.
  • Material for EBV detection by immunohistochemistry and by in situ hybridization was available in 15 of the 17 cases.
  • The squamous carcinomas were graded as well differentiated (one case), moderately differentiated (11 cases), and poorly differentiated (five cases).
  • Treatment modalities included surgical resection, radiation, chemotherapy, or a combined approach.
  • Three patients developed metastases, one of whom died of disease after 1 year.
  • Squamous carcinoma of the nasal vestibule is an uncommon cancer that is not causally related to EBV.
  • [MeSH-major] Carcinoma, Squamous Cell / virology. Herpesvirus 4, Human / isolation & purification. Nasal Cavity / virology. Nose Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10684374.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / RNA, Viral; 0 / Viral Matrix Proteins
  •  go-up   go-down


30. O'Sullivan B: Nasopharynx cancer: therapeutic value of chemoradiotherapy. Int J Radiat Oncol Biol Phys; 2007;69(2 Suppl):S118-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nasopharynx cancer: therapeutic value of chemoradiotherapy.
  • Nasopharyngeal carcinoma (NPC) is especially responsive to both chemotherapy and radiotherapy.
  • Distant relapse in NPC is generally fatal and usually relates to advanced-stage presentation, and especially extensive regional lymph node involvement, but also to the presence of the less-differentiated histologic patterns of disease that predominate in the endemic-disease areas of the world.
  • Recent improvements in survival are likely attributable to the adoption of concurrent chemotherapy as a predominant approach, although distant metastases remain as a significant cause of death.
  • Survival improvements probably do not always relate to the use of chemotherapy.
  • The randomized trials in the English literature designed to address the impact of chemotherapy on the survival of NPC patients are discussed.
  • [MeSH-major] Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Randomized Controlled Trials as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17848277.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 10
  •  go-up   go-down


31. Levendag PC, Lagerwaard FJ, de Pan C, Noever I, van Nimwegen A, Wijers O, Nowak PJ: High-dose, high-precision treatment options for boosting cancer of the nasopharynx. Radiother Oncol; 2002 Apr;63(1):67-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose, high-precision treatment options for boosting cancer of the nasopharynx.
  • PURPOSE: The aim of the study is to define the role and type of high-dose, high-precision radiation therapy for boosting early staged T1,2a, but in particular locally advanced, T2b-4, nasopharyngeal cancer (NPC).
  • MATERIALS AND METHODS: Ninety-one patients with primary stage I-IVB NPC, were treated between 1991 and 2000 with 60-70Gy external beam radiation therapy (ERT) followed by 11-18Gy endocavitary brachytherapy (ECBT) boost.
  • In 1996, for stage III-IVB disease, cisplatinum (CDDP)-based neoadjuvant chemotherapy (CHT) was introduced per protocol.
  • After matching with pre-treatment computed tomogram, patients (response) were graded into four categories; i.e.
  • Dose distributions for ECBT (Plato-BPS v. 13.3, Nucletron) were compared to parallel-opposed three-dimensional conformal radiation therapy (Cadplan, Varian Dosetek v. 3.1), intensity modulated radiation therapy (IMRT) (Helios, Varian) and stereotactic radiotherapy (SRT) (X-plan, Radionics v. 2.02).
  • For the poorest subset of patients, well/moderate/poorly differentiated T3,4 tumors, local control and overall survival at 2 years with CHT were 67 and 67%, respectively, vs. local control of 20% and overall survival of 12% without CHT.
  • CONCLUSIONS: The dosimetric findings, ease of application of the brachytherapy procedure, and the clinical results in early staged NPC, necessitates ERT combined with brachytherapy boost to be the therapy of preference for LD and LRD.
  • For locally advanced T3,4 tumors, our current protocol indicates neoadjuvant chemotherapy in conjunction with high cumulative doses of radiotherapy (81Gy); IMRT and/or SRT to be the preferred technique for boosting the primary tumor.
  • [MeSH-major] Brachytherapy / methods. Carcinoma / radiotherapy. Dose Fractionation. Nasopharyngeal Neoplasms / radiotherapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Humans. Neoadjuvant Therapy. Neoplasm Staging. Radiotherapy, Conformal / methods. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12065105.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


32. Ali SM, Olivo M: Bio-distribution and subcellular localization of Hypericin and its role in PDT induced apoptosis in cancer cells. Int J Oncol; 2002 Sep;21(3):531-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The development of new-generation photosensitizers to improve photodynamic therapy (PDT) and photodynamic diagnosis (PDD) is an area of extensive research.
  • To study the mechanism of action we have investigated uptake, intracellular localization, cell phototoxicity and morphological changes especially to ultrastructures following photodynamic treatment in poorly (CNE2) and moderately (TW0-1) differentiated human nasopharyngeal carcinoma (NPC) cells and also other tumor cells such as colon (CCL-220.1) and bladder (SD) cells in vitro.
  • Electron microscopy revealed damage to plasma membrane with high drug dose (>5 microM); indicating a mechanism related to necrosis, whereas sub-lethal lower doses (<2.5 microM) resulted in induction of apoptosis indicated by typical ultrastructural signs of apoptosis.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Apoptosis / drug effects. Neoplasms / metabolism. Perylene / analogs & derivatives. Perylene / pharmacokinetics. Photochemotherapy / methods. Photosensitizing Agents / pharmacokinetics
  • [MeSH-minor] Colonic Neoplasms / drug therapy. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Cytochrome c Group / secretion. Humans. Intracellular Membranes / drug effects. Intracellular Membranes / physiology. Lysosomes / metabolism. Membrane Potentials / drug effects. Membrane Potentials / physiology. Microscopy, Electron. Mitochondria / drug effects. Mitochondria / physiology. Mitochondria / secretion. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / metabolism. Nasopharyngeal Neoplasms / pathology. Subcellular Fractions / metabolism. Tissue Distribution. Tumor Cells, Cultured. Tumor Suppressor Protein p53 / biosynthesis. Urinary Bladder Neoplasms / drug therapy. Urinary Bladder Neoplasms / metabolism. Urinary Bladder Neoplasms / pathology

  • Hazardous Substances Data Bank. PERYLENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12168096.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cytochrome c Group; 0 / Photosensitizing Agents; 0 / Tumor Suppressor Protein p53; 5QD5427UN7 / Perylene; 7V2F1075HD / hypericin
  •  go-up   go-down


33. Torre V, Cavallari V, Bucolo S, Abbate G, Romano G, Fera G, Galletti B: [Description of a particular case of the so-called Schmincke lymphoepithelioma and study of the correlation with Epstein-Barr virus]. Acta Otorhinolaryngol Ital; 2000 Oct;20(5):347-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For poorly differentiated rhinopharyngeal carcinomas, the clinical presentation (association with the Epstein-Barr virus, paraneoplastic syndromes, onset of lymphoma) and the histopathological features can be polymorphous and they can confound or delay diagnosis and preparation of an adequate treatment plan (radio-chemotherapy).
  • Here an observation of this type is presented in a young patient (19 years old) who came under observation for a laterocervical tumefaction recurrent from a previous exeresis performed at another hospital and symptoms of serotine febricula, dysphagia and serology positive for the Epstein-Barr virus (EBV).
  • The particular histology of the neoformation lies in the abundant infiltration of plasma cell and lymphocyte eosinophils, at times in blastic form.
  • Moreover, elements with a large clear nucleus and evident nucleolus (Hodgkin-like) and scattered multinucleate Langhans-type giant cells can be seen.
  • The clear cytokeratin-positivity of the tumor elements and the histological and ultrastructural features mentioned led to the diagnosis of a massive metastasis from lymphoepithelial carcinoma, the Schmincke variant, plus EBV infection of the neoplastic cells.
  • [MeSH-major] Carcinoma, Squamous Cell / virology. Epstein-Barr Virus Infections / complications. Nasopharyngeal Neoplasms / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11284263.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


34. Ali SM, Olivo M: Mechanisms of action of phenanthroperylenequinones in photodynamic therapy (review). Int J Oncol; 2003 Jun;22(6):1181-91
Hazardous Substances Data Bank. PERYLENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanisms of action of phenanthroperylenequinones in photodynamic therapy (review).
  • Photodynamic therapy (PDT), a new mode of treatment, is based on the combined use of light-absorbing compounds and light irradiation.
  • To study the signaling mechanism in vitro we have investigated uptake kinetics, intracellular localization, mode of cell death and mechanisms involved in the photodynamic action following PDT in human cell lines of poorly differentiated (CNE2) and moderately differentiated (TW0-1) nasopharyngeal carcinoma (NPC) and also poorly differentiated colon (CCL-220.1) and bladder (SD) cells.
  • [MeSH-major] Neoplasms / drug therapy. Perylene / analogs & derivatives. Perylene / therapeutic use. Phenanthrenes / therapeutic use. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Quinones / therapeutic use
  • [MeSH-minor] Apoptosis / drug effects. Cell Death / drug effects. Humans. Models, Biological. Nitric Oxide / physiology. Phytotherapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12738982.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Phenanthrenes; 0 / Photosensitizing Agents; 0 / Quinones; 31C4KY9ESH / Nitric Oxide; 5QD5427UN7 / Perylene
  • [Number-of-references] 131
  •  go-up   go-down






Advertisement